 Rutherford, N.J., Oct. 28, 2020 GLOBE NEWSWIRE -- Cancer Genetics, Inc. Nasdaq: CGIX Cancer Genetics, a leader in drug discovery and preclinical oncology and immuno-oncology services, announced today that, due to demand, the underwriter has agreed to increase the size of the previously announced public offering and purchase on a firm commitment basis 1,363,637 shares of common stock of the Company at a price to the public of 2.20 per share, less underwriting discounts and commissions. The offering is expected to close on or about November 2, 2020, subject to satisfaction of customary closing conditions. 